In this study the study team hypothesizes MR images will identify high-grade cancers earlier
and more frequently in men at high risk of developing prostate cancer. Subjects will receive
gadolinium (intravenous contrast agent) as part of their research MRI exam. While the
deposition of gadolinium (Gd) has been demonstrated in numerous studies, the clinical
consequences of Gd deposition are unknown. Gd enhanced MRI scans provide crucial medical
information regarding prostate and prostate cancer imaging and contrast-enhanced images are a
component of all guidelines and the PIRADS scoring system. The study team will compare
baseline prostate MR images of men at high risk of developing prostate cancer to those
without an identifiable predisposition and evaluate the role of a GRS in screening men with
at elevated risk of being diagnosed with prostate cancer.